RAC Stock Overview
Race Oncology Limited operates as a precision oncology company in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.99 |
| 52 Week High | AU$3.14 |
| 52 Week Low | AU$1.45 |
| Beta | 1.78 |
| 1 Month Change | -1.00% |
| 3 Month Change | -17.43% |
| 1 Year Change | -32.08% |
| 3 Year Change | 729.17% |
| 5 Year Change | 337.36% |
| Change since IPO | 650.94% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 14
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Apr 01We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Apr 05What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?
Mar 01How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?
Jan 07
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -0.5% | -1.4% | 0.6% |
| 1Y | -32.1% | 11.8% | 3.5% |
Return vs Industry: RAC underperformed the Australian Biotechs industry which returned 11.8% over the past year.
Return vs Market: RAC underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RAC is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: RAC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Phil Lynch | https://www.raceoncology.com |
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations.
Race Oncology Limited Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market Cap | AU$320.77m |
| Earnings (TTM) | -AU$11.20m |
| Revenue (TTM) | AU$761.72k |
421.1x
P/S Ratio-28.6x
P/E RatioIs RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$761.72k |
| Cost of Revenue | AU$990.26k |
| Gross Profit | -AU$228.54k |
| Other Expenses | AU$10.97m |
| Earnings | -AU$11.20m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | -30.00% |
| Net Profit Margin | -1,470.61% |
| Debt/Equity Ratio | 0% |
How did RAC perform over the long term?
See historical performance and comparison